OpenURL Connection Search

Select item for more details and to access through your institution.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Published in:
Clinical Infectious Diseases, 2023, v. 76, n. 9, p. 1646, doi. 10.1093/cid/ciad020
By:
- Overton, Edgar T;
- Richmond, Gary;
- Rizzardini, Giuliano;
- Thalme, Anders;
- Girard, Pierre-Marie;
- Wong, Alexander;
- Porteiro, Norma;
- Swindells, Susan;
- Reynes, Jacques;
- Noe, Sebastian;
- Harrington, Conn;
- Español, Carlos Martín;
- Acuipil, Carolina;
- Aksar, Asma;
- Wang, Yuanyuan;
- Ford, Susan L;
- Crauwels, Herta;
- Eygen, Veerle van;
- Solingen-Ristea, Rodica Van;
- Latham, Christine L
Publication type:
Article
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.
Published in:
Open Forum Infectious Diseases, 2019, v. 6, p. S20, doi. 10.1093/ofid/ofz359.043
By:
- Teichner, Paula;
- Cutrell, Amy;
- D'Amico, Ronald;
- Dorey, David;
- Griffith, Sandy;
- Harrington, Conn M;
- Huang, Jenny;
- Hudson, Krischan J;
- Margolis, David;
- Mrus, Joseph;
- Polli, Joseph;
- Spreen, William;
- Williams, Peter;
- Solingen-Ristea, Rodica Van;
- Shaefer, Mark S
Publication type:
Article
THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1.
Published in:
Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 204
By:
- Felizarta, Franco;
- D'Amico, Ronald;
- Wang, Kehui;
- Crauwels, Herta;
- Masiá, Mar;
- Deltoro, Miguel Garcia;
- Degen, Olaf;
- Angel, Jonathan;
- Hsiao, Chiu-Bin;
- Chounta, Vasiliki;
- Han, Kelong;
- Harrington, Conn;
- Rimler, Kelly;
- Spreen, William R.;
- Ford, Susan
Publication type:
Article
Safety profile of cabotegravir + rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the phase 3 FLAIR, ATLAS, and ATLAS-2M studies.
Published in:
Infection & Chemotherapy, 2022, v. 54, p. S304
By:
- de los Rios, Patricia;
- Patel, Parul;
- Huang, Jenny;
- Harrington, Conn;
- D’Amico, Ronald;
- Thiagarajah, Shanker;
- Birmingham, Eileen;
- Van Solingen-Ristea, Rodica;
- Spreen, William R.;
- Baugh, Bryan;
- Jun Yong Choi;
- Bosse, Matt
Publication type:
Article

Found: 4

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.

THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1.

Safety profile of cabotegravir + rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the phase 3 FLAIR, ATLAS, and ATLAS-2M studies.